Organogenesis (NASDAQ:ORGO) Shares Gap Up – Still a Buy?

Organogenesis Holdings Inc. (NASDAQ:ORGO) gapped up prior to trading on Wednesday . The stock had previously closed at $3.45, but opened at $3.85. Organogenesis shares last traded at $4.34, with a volume of 290,034 shares changing hands.

Organogenesis Stock Up 19.1 %

The business has a 50-day moving average of $2.92 and a 200-day moving average of $2.79. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.73 and a quick ratio of 2.42.

Institutional Trading of Organogenesis

A number of hedge funds have recently added to or reduced their stakes in ORGO. Assenagon Asset Management S.A. increased its stake in Organogenesis by 309.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock valued at $11,136,000 after purchasing an additional 3,005,450 shares in the last quarter. Acadian Asset Management LLC increased its stake in Organogenesis by 2.4% in the 2nd quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after purchasing an additional 72,696 shares in the last quarter. AQR Capital Management LLC increased its stake in Organogenesis by 76.9% in the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock valued at $6,353,000 after purchasing an additional 986,132 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Organogenesis by 19.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after purchasing an additional 333,123 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Organogenesis by 2.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock worth $2,713,000 after purchasing an additional 23,675 shares during the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.